ArticleCancer immunology, immunotherapy : CII2008
Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Progress in the development of cancer vaccines for lung cancer utilizing dendritic cells (Review).Oncology letters · 2025Review
- Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice.Molecular cancer research : MCR · 2024Article
- HSP90 multi-functionality in cancer.Frontiers in immunology · 2024Review
- Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.Cells · 2023Review
- Comprehensive analysis reveals GRP94 is associated with worse prognosis of breast cancer.Translational cancer research · 2021Article
- The HSP Immune Network in Cancer.Frontiers in immunology · 2021Review
- Molecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target.Frontiers in oncology · 2021Review
- Disease swamps molecular signatures of genetic-environmental associations to abiotic factors in Tasmanian devil (Sarcophilus harrisii) populations.Evolution; international journal of organic evolution · 2020Article
- Article
- Current State of Dendritic Cell-Based Immunotherapy: Opportunities forFrontiers in immunology · 2018Review
- Article
- Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation.World journal of gastroenterology · 2017Article
- Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94.Current topics in medicinal chemistry · 2016Review
- Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells.Oncology reports · 2015Article
- Expression of heat-shock protein gp96 in gallbladder cancer and its prognostic clinical significance.International journal of clinical and experimental pathology · 2015Article
- Dendritic-tumor fusion cells derived heat shock protein70-peptide complex has enhanced immunogenicity.PloS one · 2015Article
- Tumor immunotherapy based on tumor-derived heat shock proteins (Review).Oncology letters · 2013Article
- A model of dendritic cell therapy for melanoma.Frontiers in oncology · 2013Article
- NK cells: key to success of DC-based cancer vaccines?The oncologist · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeImmunization with heat shock proteins, gp96, elicits specific protective immunity against parent tumors. However, it is marginally effective as a therapeutic tool against established tumors. In the present study, we evaluated the efficacy and mechanism of immunotherapy with bone marrow-derived dendritic cells (DCs) pulsed with tumor-derived gp96 against murine lung cancer.
methodsMice were transplanted subcutaneously with ovalbumin (OVA)-transfected Lewis Lung Cancer (LLC-OVA) cells and immunized with gp96 derived from LLC-OVA, DCs, or DCs pulsed with gp96 derived from LLC-OVA.
resultsThe antitumor effect was significantly enhanced in the mice immunized with DCs pulsed with gp96 derived from LLC-OVA, compared to mice immunized with gp96 or DCs (P<0.05). The antitumor effect was significantly dependent on natural killer (NK) cells and CD8(+) cells and partially dependent on CD4(+) cells. Analysis by laser confocal microscopy demonstrated that gp96 was shown on the cell surface at 15 min, and after 30 min internalized in the endosomes and not in the endoplasmic reticulum or lysosomes. OVA-specific(+) CD8(+) cells were more readily recruited into the draining lymph nodes and higher CD8(+) cytotoxic T cell activity against LLC-OVA was observed in splenocytes from mice immunized with DCs pulsed with gp96 derived from LLC-OVA. Re-challenge of the surviving mice with LLC-OVA tumors after the initial tumor inoculation showed dramatic retardation in tumor growth.
conclusionIn conclusion, immunotherapy of DCs pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8(+) cytotoxic T lymphocytes and NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.